#USA #Boulder #Foresight Diagnostics #Allogene Therapeutics #MRD Detection

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics

Foresight Diagnostics, a prominent player in ultra-sensitive minimal residual disease (MRD) detection technology, has announced a significant enhancement of its partnership with Allogene Therapeutics. This expanded collaboration aims to propel the development of MRD assays across various regions, including Europe, the UK, Canada, and Australia, following recent strategic advancements.

Key Details of the Partnership

The partnership now includes important components such as investments in further MRD assay development, the testing of clinical samples, and milestone payments aimed at international expansion. Specifically, Foresight Diagnostics and Allogene Therapeutics will collaborate on developing the MRD assay as a companion diagnostic. This diagnostic tool is set to identify patients with large B-cell lymphoma (LBCL) who are eligible for treatment via cemacabtagene ansegedleucel (cema-cel) in Allogene's innovative ALPHA3 clinical trial.

Cema-cel is undergoing investigation in a pivotal randomized controlled trial that represents a groundbreaking first-line treatment aimed at improving cure rates for LBCL patients. In the ALPHA3 trial, there exists a critical opportunity for patients who attain remission but remain MRD-positive. Utilizing the Foresight CLARITY™ IUO assay, these patients may receive a one-time consolidation dose of cema-cel to help prevent disease recurrence.

Insights from Leadership

Sandra Close, PhD, Chief Operations and Compliance Officer of Foresight Diagnostics, articulated enthusiasm over this expanded partnership. She noted, "We are excited about our expanded collaboration with Allogene which will enable development of our MRD assay beyond the U.S. This is an important milestone as we continue to support our biopharma partners implementing MRD-driven clinical trials globally."

This strategic move not only underscores Foresight Diagnostics' commitment to enhancing cancer diagnostics but also reflects its goal to make significant strides in areas where MRD detection can play a crucial role in patient outcomes.

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics entity and a CLIA-certified laboratory specializing in advanced liquid biopsy technology through its Foresight CLARITY™ platform. This innovative assay is designed to measure minimal residual disease with extraordinary sensitivity, reported in parts per million. The superior detection capabilities of Foresight CLARITY™ aim to furnish actionable insights for healthcare professionals and biopharmaceutical companies, facilitating personalized treatment strategies for patients grappling with solid tumors and hematologic malignancies.

In their quest for excellence, Foresight Diagnostics continues to engage in robust research and development efforts, paving the way for advanced diagnostic paradigms that have the potential to revolutionize cancer treatment.

For further information, please visit foresight-dx.com and follow the company on platforms like X, LinkedIn, and Bluesky. Note that Foresight CLARITY™ IUO is classified as an investigational device, which is limited to investigational use under United States law.

Conclusion

This strengthened collaboration between Foresight Diagnostics and Allogene Therapeutics marks a pivotal step towards broader and more impactful MRD detection initiatives globally. The collective expertise and resources from both companies are expected to significantly contribute to advancing cancer treatment, making patient care more effective and personalized.